SCHEMBL2276583

SCHEMBL2276583

Cc1ccccc1Oc1ccc(C(=O)O)c(NC(=O)c2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PYGM P11217 5/20 0.61
PYGL P06737 5/20 0.61
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
PKM P14618 2/20 0.54
MAPT P10636 1/20 0.54
GRIK1 P39086 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NR1H4 Q96RI1 1/20 0.50
GCK P35557 1/20 0.49
KCNK2 O95069 1/20 0.49
KCNK10 P57789 1/20 0.49
HPSE Q9Y251 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275737 0.92 POLB (0.60) PYGMPYGLMEN1KMT2APKM
SCHEMBL2269635 0.90 PYGM (0.56) PYGMPYGLMEN1KMT2APKM
SCHEMBL2272615 0.88 PYGM (0.55) PYGMPYGLMEN1KMT2APKM
SCHEMBL2270304 0.87 MEN1 (0.61) PYGMPYGLMEN1KMT2APKM
SCHEMBL2269896 0.86 TDP1 (0.58) PYGMPYGLMEN1KMT2APKM
SCHEMBL2292384 0.86 MEN1 (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2271528 0.85 PYGM (0.61) PYGMPYGLMEN1KMT2APKM
SCHEMBL2271217 0.85 PYGM (0.61) PYGMPYGLMEN1KMT2APKM
SCHEMBL2273044 0.85 CYP2C9 (0.61) PYGMPYGLMEN1KMT2APKM
SCHEMBL2271588 0.84 SERPINE1 (0.64) PYGMPYGLMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PYGM 1299/4885PYGL 1834/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.